<DOC>
	<DOCNO>NCT00217438</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy drug , melphalan , work different way stop growth cancer cell , either kill cell stop dividing . Chemoprotective drug , amifostine , may protect normal cell side effect chemotherapy . Giving chemotherapy peripheral stem cell transplant twice , use stem cell patient identical brother sister , may allow chemotherapy give cancer cell kill . Giving maintenance therapy stem cell transplant may kill cancer cell remain . It yet know dose melphalan effective treat multiple myeloma ( MM ) . PURPOSE : This randomized phase III trial study two different dos melphalan compare well work give together amifostine follow one two autologous syngeneic stem cell transplant maintenance therapy treat patient stage II-III MM</brief_summary>
	<brief_title>Melphalan Amifostine Followed By One Two Autologous Syngeneic Stem Cell Transplants Maintenance Therapy Treating Patients With Stage II-III Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Compare complete response ( CR ) near CR rate patient undergo autologous stem cell transplant ( ASCT ) use melphalan 280 mg/m^2 melphalan 200 mg/m^2 . SECONDARY OBJECTIVES : I . Compare toxicities patient receive amifostine melphalan 280 mg/m^2 melphalan 200 mg/m^2 . OUTLINE : Patients randomize 1 2 treatment arm . INDUCTION THERAPY : ARM I ( HIGH DOSE MELPHALAN AND AMIFOSTINE ) : Patients receive amifostine intravenously ( IV ) 3-5 minute day -3 -2 follow high-dose melphalan IV 15-30 minute day 2 . ARM II ( LOW DOSE MELPHALAN AND AMIFOSTINE ) : Patients receive amifostine arm I melphalan arm I low dose . AUTOLOGOUS OR SYNGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION ( PBSCT ) : At least 20 hour completion melphalan , patient undergo autologous syngeneic PBSCT day 0 . Patients undergo restaging disease day 80-90 . Patients progressive disease remove study . Patients achieve CR near-CR proceed optional maintenance therapy . Patients achieve CR near-CR may undergo additional induction therapy arm I follow second autologous syngeneic PBSCT . Patients undergo restaging disease 80-90 day later . Patients progressive disease remove study . Patients without progressive disease proceed maintenance therapy . After completion study treatment , patient follow every 3 month 5 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Patients MM undergo autologous syngeneic hematopoietic transplantation Patients must meet Salmon Durie criterion initial diagnosis MM Transplant offer patient stage II III MM Measurable disease , define serum monoclonal protein &gt; = 0.2 g/dl Bence Jones protein &gt; = 200 mg/24 h Karnofsky &gt; = 70 Eastern Cooperative Oncology Group ( ECOG ) 02 Life expectancy severely limited concomitant illness Left ventricular ejection fraction &gt; = 50 % No uncontrolled arrhythmias symptomatic cardiac disease Forced expiratory volume one second ( FEV1 ) , force vital capacity ( FVC ) , diffusion capacity carbon monoxide ( DLCO ) &gt; = 50 % No symptomatic pulmonary disease Human immunodeficiency virus ( HIV ) negative Bilirubin &lt; 2 mg/dl Serum glutamic pyruvate transaminase ( SGPT ) &lt; 2.5 x normal Creatinine clearance &gt; = 60 cc/min , estimate measure Signed inform consent Pregnant lactating female Uncontrolled infection Planned tandem autologous/reduced intensity allograft Insufficient PBSC autologous transplant ( &lt; 3.0 x 10^6 CD34+ cells/kg total ) Prior autologous transplant Nonsecretory myeloma patient complete response near complete response conventional therapy Patients unwilling practice adequate form contraception clinically indicate Male patient study need consult use latex condom , even vasectomy , every time sex woman able child Patients history seizures Patients receive antihypertensive therapy stop 24 hour precede amifostine treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>